MX9308053A - COMBINACION DE UN INHIBIDOR DE LA BIOSINTESIS DE COLESTEROL Y UN INHIBIDOR DE ABSORCION DE COLESTEROL DE ß-LACTAMA. - Google Patents

COMBINACION DE UN INHIBIDOR DE LA BIOSINTESIS DE COLESTEROL Y UN INHIBIDOR DE ABSORCION DE COLESTEROL DE ß-LACTAMA.

Info

Publication number
MX9308053A
MX9308053A MX9308053A MX9308053A MX9308053A MX 9308053 A MX9308053 A MX 9308053A MX 9308053 A MX9308053 A MX 9308053A MX 9308053 A MX9308053 A MX 9308053A MX 9308053 A MX9308053 A MX 9308053A
Authority
MX
Mexico
Prior art keywords
inhibitor
cholesterol
pct
combination
lactam
Prior art date
Application number
MX9308053A
Other languages
English (en)
Inventor
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9308053A publication Critical patent/MX9308053A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para reducir los niveles de colesterol en el plasma y para tratar o prevenir la ateroesclerosis, que comprende administrar una cantidad eficaz de una combinación de un inhibidor de biosíntesis de colesterol y un inhibidor de absorción de colesterol de ß-lactama, así como también composiciones farmacéuticas y equipos que son útiles en estos métodos.
MX9308053A 1992-12-23 1993-12-13 COMBINACION DE UN INHIBIDOR DE LA BIOSINTESIS DE COLESTEROL Y UN INHIBIDOR DE ABSORCION DE COLESTEROL DE ß-LACTAMA. MX9308053A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (1)

Publication Number Publication Date
MX9308053A true MX9308053A (es) 1994-06-30

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9308053A MX9308053A (es) 1992-12-23 1993-12-13 COMBINACION DE UN INHIBIDOR DE LA BIOSINTESIS DE COLESTEROL Y UN INHIBIDOR DE ABSORCION DE COLESTEROL DE ß-LACTAMA.

Country Status (32)

Country Link
US (1) US5661145A (es)
EP (1) EP0675714B1 (es)
JP (1) JP3992728B2 (es)
KR (1) KR100306936B1 (es)
CN (1) CN1090479C (es)
AT (1) ATE175872T1 (es)
AU (1) AU680864B2 (es)
CA (1) CA2152351C (es)
CZ (1) CZ287125B6 (es)
DE (1) DE69323213T2 (es)
DK (1) DK0675714T3 (es)
EE (1) EE03383B1 (es)
ES (1) ES2128552T3 (es)
FI (1) FI952916A (es)
GR (1) GR3029405T3 (es)
HR (1) HRP931515B1 (es)
HU (1) HU221724B1 (es)
IL (1) IL108112A (es)
LT (1) LT3300B (es)
LV (1) LV10919B (es)
MX (1) MX9308053A (es)
MY (1) MY109538A (es)
NO (1) NO311325B1 (es)
NZ (1) NZ259790A (es)
PL (1) PL174128B1 (es)
SG (1) SG45147A1 (es)
SI (1) SI9300677A (es)
SK (1) SK281173B6 (es)
TW (1) TW319698B (es)
WO (1) WO1994014433A1 (es)
YU (1) YU49060B (es)
ZA (1) ZA939552B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
HUP9901865A3 (en) 1995-11-02 2000-06-28 Warner Lambert Co Method and pharmaceutical composition for regulating lipid concentration
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
AU783457B2 (en) * 2000-04-05 2005-10-27 Toray Industries, Inc. Adsorbents for high mobility group proteins and column for purifying body fluid
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1915429B (zh) * 2001-01-26 2010-12-15 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CZ304929B6 (cs) 2001-03-28 2015-01-28 Merck Sharp & Dohme Corp. Enantioselektivní syntéza azetidinonových meziproduktů
SI1427409T1 (sl) * 2001-09-21 2009-02-28 Schering Corp Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
CA2460340C (en) * 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
MXPA05009503A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005062824A2 (en) * 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US7901893B2 (en) * 2004-01-16 2011-03-08 Merck Sharp & Dohme Corp. NPC1L1 (NPC3) and methods of identifying ligands thereof
SG187416A1 (en) * 2004-07-01 2013-02-28 Opko Health Inc Piperidine derivatives as nk1 antagonists
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (es) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
KR20080021082A (ko) * 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 h3 길항제로서 유용한 피페리딘 유도체
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en) * 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
EP2059241A1 (en) * 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
EA201101231A1 (ru) 2009-03-27 2012-06-29 Бристол-Майерс Сквибб Компани Способы предотвращения или снижения риска смертности
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
JP2021530517A (ja) 2018-07-19 2021-11-11 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag ダパグリフロジンを使用してHFpEFを処置する方法、及びダパグリフロジンを含む組成物
KR20240021883A (ko) 2021-06-16 2024-02-19 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
IL102582A0 (en) * 1991-07-23 1993-01-14 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US9205972B2 (en) 2012-01-26 2015-12-08 Intralot S.A.—Integrated Lottery Systems and Services Methods and systems for dispensing

Also Published As

Publication number Publication date
CN1095591A (zh) 1994-11-30
KR100306936B1 (ko) 2001-11-30
TW319698B (es) 1997-11-11
ZA939552B (en) 1994-10-12
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
SI9300677A (en) 1994-09-30
CZ287125B6 (en) 2000-09-13
AU5872094A (en) 1994-07-19
EE9400341A (et) 1996-04-15
AU680864B2 (en) 1997-08-14
NZ259790A (en) 1997-02-24
SG45147A1 (en) 1998-01-16
CA2152351C (en) 2009-09-22
WO1994014433A1 (en) 1994-07-07
LV10919B (en) 1996-04-20
EP0675714B1 (en) 1999-01-20
CA2152351A1 (en) 1994-07-07
DE69323213T2 (de) 1999-07-08
EP0675714A1 (en) 1995-10-11
IL108112A (en) 1999-11-30
YU80293A (sh) 1997-12-05
NO952529D0 (no) 1995-06-23
SK281173B6 (sk) 2000-12-11
DE69323213D1 (de) 1999-03-04
LT3300B (en) 1995-06-26
EE03383B1 (et) 2001-04-16
LTIP1514A (en) 1994-10-25
IL108112A0 (en) 1994-04-12
US5661145A (en) 1997-08-26
FI952916A0 (fi) 1995-06-14
LV10919A (lv) 1995-12-20
FI952916A (fi) 1995-06-14
HU9501854D0 (en) 1995-08-28
YU49060B (sh) 2003-08-29
HUT72081A (en) 1996-03-28
SK78395A3 (en) 1996-05-08
DK0675714T3 (da) 1999-09-13
HRP931515A2 (en) 1996-12-31
HRP931515B1 (en) 2000-02-29
HU221724B1 (hu) 2002-12-28
ATE175872T1 (de) 1999-02-15
JP3992728B2 (ja) 2007-10-17
CN1090479C (zh) 2002-09-11
PL309636A1 (en) 1995-10-30
GR3029405T3 (en) 1999-05-28
CZ164395A3 (en) 1996-03-13
MY109538A (en) 1997-02-28
JPH08505141A (ja) 1996-06-04
NO952529L (no) 1995-06-23
ES2128552T3 (es) 1999-05-16

Similar Documents

Publication Publication Date Title
MX9308053A (es) COMBINACION DE UN INHIBIDOR DE LA BIOSINTESIS DE COLESTEROL Y UN INHIBIDOR DE ABSORCION DE COLESTEROL DE ß-LACTAMA.
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ES2131185T3 (es) Arilalcanil-n-hidroxiureas y heteroalquilalcanil-n-hidroxiureas sustituidas que pueden inhibir la biosintesis de leucotrienos.
BR9908857A (pt) Métodos e composições para tratamento, inibição e prevenção de mucosite
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
AU4923093A (en) Inhibitors of metazoan parasite proteases
EP0646007A4 (es)
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
EP0674521A4 (en) METHOD FOR TREATING CHRONIC PROSTATITIS WITH 17-BETA-N MONO SUBSTITUTED CARBAMOYL-4-AZA-5 ALPHA-ANDROST-1-EN-3-ONES.
ES2187775T3 (es) Imidazopiridinas.
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
HK1024872A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ